Allison M Jay1, Robert L Conway1, Gerald L Feldman2, Fatimah Nahhas3, Linda Spencer1, Barry Wolf4. 1. Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA. 2. 1] Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA [2] Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA [3] Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA. 3. 1] Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA [2] Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA. 4. 1] Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA [2] Genetics Research Laboratory, Department of Research Administration, Henry Ford Hospital, Detroit, Michigan, USA.
Abstract
PURPOSE: Biotinidase deficiency, if untreated, usually results in neurological and cutaneous symptoms. Biotin supplementation markedly improves and likely prevents symptoms in those treated early. All states in the United States and many countries perform newborn screening for biotinidase deficiency. However, there are few studies about the outcomes of the individuals identified by newborn screening. METHODS: We report the outcomes of 142 children with biotinidase deficiency identified by newborn screening in Michigan over a 25-year period and followed in our clinic; 22 had profound deficiency and 120 had partial deficiency. RESULTS: Individuals with profound biotinidase and partial deficiency identified by newborn screening were started on biotin therapy soon after birth. With good compliance, these children appeared to have normal physical and cognitive development. Although some children exhibited mild clinical problems, these are unlikely attributable to the disorder. Biotin therapy appears to prevent the development of neurological and cutaneous problems in our population. CONCLUSION: Individuals with biotinidase deficiency ascertained by newborn screening and treated since birth appeared to exhibit normal physical and cognitive development. If an individual does develop symptoms, after compliance and dosage issues are excluded, then other causes must be considered.Genet Med 17 3, 205-209.
PURPOSE: Biotinidase deficiency, if untreated, usually results in neurological and cutaneous symptoms. Biotin supplementation markedly improves and likely prevents symptoms in those treated early. All states in the United States and many countries perform newborn screening for biotinidase deficiency. However, there are few studies about the outcomes of the individuals identified by newborn screening. METHODS: We report the outcomes of 142 children with biotinidase deficiency identified by newborn screening in Michigan over a 25-year period and followed in our clinic; 22 had profound deficiency and 120 had partial deficiency. RESULTS: Individuals with profound biotinidase and partial deficiency identified by newborn screening were started on biotin therapy soon after birth. With good compliance, these children appeared to have normal physical and cognitive development. Although some children exhibited mild clinical problems, these are unlikely attributable to the disorder. Biotin therapy appears to prevent the development of neurological and cutaneous problems in our population. CONCLUSION: Individuals with biotinidase deficiency ascertained by newborn screening and treated since birth appeared to exhibit normal physical and cognitive development. If an individual does develop symptoms, after compliance and dosage issues are excluded, then other causes must be considered.Genet Med 17 3, 205-209.
Authors: Rachel C Wiltink; Michelle E Kruijshaar; Rick van Minkelen; Willem Onkenhout; Frans W Verheijen; Evelien A Kemper; Francjan J van Spronsen; Ans T van der Ploeg; Klary E Niezen-Koning; Jasper J Saris; Monique Williams Journal: Eur J Hum Genet Date: 2016-06-22 Impact factor: 4.246
Authors: Daniela Semeraro; Sara Verrocchio; Giulia Di Dalmazi; Claudia Rossi; Damiana Pieragostino; Ilaria Cicalini; Rossella Ferrante; Silvia Di Michele; Liborio Stuppia; Cristiano Rizzo; Francesca Romana Lepri; Antonio Novelli; Carlo Dionisi-Vici; Vincenzo De Laurenzi; Ines Bucci Journal: Int J Environ Res Public Health Date: 2022-07-02 Impact factor: 4.614
Authors: Eva M M Hoytema van Konijnenburg; Saskia B Wortmann; Marina J Koelewijn; Laura A Tseng; Roderick Houben; Sylvia Stöckler-Ipsiroglu; Carlos R Ferreira; Clara D M van Karnebeek Journal: Orphanet J Rare Dis Date: 2021-04-12 Impact factor: 4.123
Authors: Ilaria Cicalini; Damiana Pieragostino; Cristiano Rizzo; Sara Verrocchio; Daniela Semeraro; Mirco Zucchelli; Silvia Di Michele; Carlo Dionisi-Vici; Liborio Stuppia; Vincenzo De Laurenzi; Ines Bucci; Claudia Rossi Journal: Int J Environ Res Public Health Date: 2021-02-09 Impact factor: 3.390
Authors: Teegan A Dellibovi-Ragheb; Hugo Jhun; Christopher D Goodman; Maroya S Walters; Daniel R T Ragheb; Krista A Matthews; Krithika Rajaram; Satish Mishra; Geoffrey I McFadden; Photini Sinnis; Sean T Prigge Journal: Proc Natl Acad Sci U S A Date: 2018-02-26 Impact factor: 11.205
Authors: M Mardhiah; Nor Azimah Abdul Azize; Yusnita Yakob; O Affandi; Ngu Lock Hock; M R Rowani; Anasufiza Habib Journal: Mol Genet Metab Rep Date: 2019-12-19